| Tomillero A, Moral MA
Gateways to clinical trials. [Journal Article]
Methods Find Exp Clin Pharmacol 2009 Sep; 31(7):463-93.
Abstract | Full Citation |
| Luber A, Condoluci D, Slowinski P, et al.
Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers. [JOURNAL ARTICLE]
HIV Med 2009 Oct 23.
Abstract | Full Citation | Find Related Articles |
| Hill A, Sawyer W
Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients. [Journal Article]
HIV Med 2009 Oct; 10(9):527-35.
Abstract | Full Citation | Find Related Articles |
| De Clercq E
The history of antiretrovirals: key discoveries over the past 25 years. [JOURNAL ARTICLE]
Rev Med Virol 2009 Aug 27; 19(5):287-299.
Abstract | Full Citation |
| Van Houtte M, Picchio G, Van Der Borght K, et al.
A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype. [JOURNAL ARTICLE]
J Med Virol 2009 Aug 20; 81(10):1702-1709.
Abstract | Full Citation |
| Perrella A, Sbreglia C, D'Antonio A, et al.
Fosamprenavir treatment in a highly active antiretroviral therapy schedule induces a HCV-RNA decrease and a Th1 network boost in HIV/HCV-coinfected patients. [JOURNAL ARTICLE]
Clin Microbiol Infect 2009 Jul 20.
Abstract | Full Citation | Find Related Articles |
| Perez-Elias MJ, Larrousse Morellon M, Ortega E, et al.
Pharmacokinetics of Fosamprenavir plus Ritonavir in HIV-1-infected Adult Subjects with Hepatic Impairment. [JOURNAL ARTICLE]
Antimicrob Agents Chemother 2009 Aug 10.
Abstract | Full Citation | Find Related Articles |
| McRae M, Clay PG, Anderson PL, et al.
Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects. [Journal Article, Research Support, Non-U.S. Gov't]
Pharmacotherapy 2009 Aug; 29(8):937-42.
Abstract | Full Citation |
| Parks DA, Jennings HC, Taylor C, et al.
Steady-State Amprenavir, Tenofovir, and Emtricitabine Pharmacokinetics Before and After Reducing Ritonavir Boosting of a Fosamprenavir/Tenofovir/Emtricitabine Regimen from 200 mg to 100 mg Once Daily (TELEX II). [Journal Article]
HIV Clin Trials 2009 May-Jun; 10(3):160-7.
Abstract | Full Citation |
| Shuter J, Sarlo JA, Rode RA, et al.
Occurrence of Selective Ritonavir Nonadherence and Dose-Staggering in Recipients of Boosted HIV-1 Protease Inhibitor Therapy. [Journal Article]
HIV Clin Trials 2009 May-Jun; 10(3):135-42.
Abstract | Full Citation |
  |
